Personal information

Activities

Employment (2)

Ospedale San Sebastiano di Frascati: Frascati, Lazio, IT

2021-08-16 to present | Dermatologist (Dermatology)
Employment
Source: Self-asserted source
Mauro Bavetta

Fondazione PTV Policlinico Tor Vergata Dipartimento Scienze mediche: Roma, Lazio, IT

2013-08-08 to 2021-08-14 | Dermatologist (Dermatology)
Employment
Source: Self-asserted source
Mauro Bavetta

Education and qualifications (1)

Fondazione PTV Policlinico Tor Vergata Dipartimento di Medicina: Roma, Lazio, IT

2003-09 to 2010-03
Education
Source: Self-asserted source
Mauro Bavetta

Works (29)

2‐Year Experience with Risankizumab in the Treatment of Plaque Psoriasis in Lazio Region, Italy

Dermatologic Therapy
2023-01 | Journal article
Contributors: Giacomo Caldarola; Eleonora De Luca; Mauro Bavetta; Nicoletta Bernardini; Annunziata Dattola; Clara De Simone; Dario Graceffa; Claudio Bonifati; Paola Tribuzi; Domenico Giordano et al.
Source: check_circle
Crossref

Risankizumab for the treatment of moderate‐to‐severe psoriasis: A multicenter, retrospective, 1 year real‐life study

Dermatologic Therapy
2022-06 | Journal article
Contributors: Giacomo Caldarola; Arianna Zangrilli; Nicoletta Bernardini; Mauro Bavetta; Clara De Simone; Dario Graceffa; Claudio Bonifati; Sara Faleri; Domenico Giordano; Marco Mariani et al.
Source: check_circle
Crossref

Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy

Expert Opinion on Biological Therapy
2021-09-02 | Journal article
Contributors: Arianna Zangrilli; Giacomo Caldarola; Nicoletta Bernardini; Mauro Bavetta; Dario Graceffa; Claudio Bonifati; Franca Cantoresi; Sara Faleri; Domenico Giordano; Marco Mariani et al.
Source: check_circle
Crossref

Skin advanced glycation end products as a diagnostic and monitoring tool among psoriatic patients: how the therapy helps reduce cardiovascular disease risk.

International journal of dermatology
2021-08-25 | Journal article
Source: Self-asserted source
Mauro Bavetta

The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions

Journal of Clinical Medicine
2021-01-26 | Journal article
Contributors: Mauro Bavetta; Dionisio Silvaggio; Elena Campione; Pietro Sollena; Vincenzo Formica; Deborah Coletta; Grazia Graziani; Maria Concetta Pucci Romano; Mario Roselli; Ketty Peris et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

A linear forehead lesion caused by intralesional injection of triamcinolone acetonide and treated with hyaluronic acid filler: Case report

Dermatologic Therapy
2020-11-20 | Journal article
Contributors: Arianna Piccolo; Chiara Pensa; Arianna Zangrilli; Mauro Bavetta; Laura Diluvio; Luca Bianchi
Source: check_circle
Crossref

Risankizumab: How to choose the right dose in clinical practice?

Dermatologic Therapy
2020-11-20 | Journal article
Contributors: Chiara Pensa; Arianna Piccolo; Arianna Zangrilli; Mauro Bavetta; Luca Bianchi
Source: check_circle
Crossref

Ixekizumab: One drug for an enigmatic psoriasis

Dermatologic Therapy
2020-11-11 | Journal article
Contributors: Arianna Piccolo; Chiara Pensa; Arianna Zangrilli; Mauro Bavetta; Augusto Orlandi; Luca Bianchi
Source: check_circle
Crossref

Efficacy and safety of adalimumab in difficult‐to‐treat psoriasis

Dermatologic Therapy
2020-05-24 | Journal article
Contributors: Caterina Lanna; Arianna Zangrilli; Mauro Bavetta; Elena Campione; Luca Bianchi
Source: check_circle
Crossref

Psoriasis in difficult to treat areas: treatment role in improving health-related quality of life and perception of the disease stigma.

The Journal of dermatological treatment
2020-05-18 | Journal article
Source: Self-asserted source
Mauro Bavetta

Adalimumab in children and adolescents with severe plaque psoriasis: a safety evaluation.

Expert opinion on drug safety
2020-04-06 | Journal article
Source: Self-asserted source
Mauro Bavetta

<p>Omalizumab for chronic spontaneous urticaria in “complex” patients: data from real-life clinical practice</p>

Drug Design, Development and Therapy
2019-09 | Journal article
Contributors: Laura Vollono; Arianna Piccolo; Caterina Lanna; Maria Esposito; Mauro Bavetta; Elena Campione; Luca Bianchi; Laura Diluvio
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Monitoring treatment response in patients affected by actinic keratosis: Dermoscopic assessment and metalloproteinases evaluation after piroxicam 0.8% and sunfilter cream

Dermatologic Therapy
2019-01-04 | Journal article
Contributors: Laura Diluvio; Mauro Bavetta; Gaetana Costanza; Augusto Orlandi; Luca Bianchi; Elena Campione
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Expression and potential role of cellular retinol binding protein I in psoriasis.

Oncotarget
2018-12-04 | Journal article
Source: Self-asserted source
Mauro Bavetta

Paradoxical case effects of psoriasis following adalimumab therapy: A case series

Dermatologic Therapy
2018-11-21 | Journal article
Contributors: Arianna Zangrilli; Mauro Bavetta; Sara Mazzilli; Virginia Garofalo; Luca Bianchi
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice.

The Journal of dermatological treatment
2018-11-06 | Journal article
Source: Self-asserted source
Mauro Bavetta
grade
Preferred source (of 2)‎

Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia
2018-04-01 | Journal article
Source: Self-asserted source
Mauro Bavetta
grade
Preferred source (of 2)‎

Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study

Journal of the European Academy of Dermatology and Venereology
2017 | Journal article
EID:

2-s2.0-84977098204

Part of ISBN:

14683083 09269959

Contributors: Chiricozzi, A.; Zangrilli, A.; Bavetta, M.; Bianchi, L.; Chimenti, S.; Saraceno, R.
Source: Self-asserted source
Mauro Bavetta via Scopus - Elsevier

Is weekly dose of adalimumab a simple approach for resistant psoriasis?

The Journal of dermatological treatment
2017-08-18 | Journal article
Source: Self-asserted source
Mauro Bavetta
grade
Preferred source (of 2)‎

HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.

Molecular diagnosis & therapy
2017-06-01 | Journal article
Source: Self-asserted source
Mauro Bavetta
grade
Preferred source (of 2)‎

Dermoscopic monitoring of efficacy of ingenol mebutate in the treatment of pigmented and non-pigmented basal cell carcinomas.

Dermatologic therapy
2016-11-12 | Journal article
Source: Self-asserted source
Mauro Bavetta
grade
Preferred source (of 2)‎

Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk.

European journal of dermatology : EJD
2015-01-01 | Journal article
Source: Self-asserted source
Mauro Bavetta
grade
Preferred source (of 2)‎

Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations.

Drug development research
2014-11-01 | Journal article
Source: Self-asserted source
Mauro Bavetta
grade
Preferred source (of 2)‎

Etanercept reverses downregulation of inhibitor of nuclear factor kappa-B kinase subunit alpha (IKKa) in psoriasis

Clinical Drug Investigation
2013 | Journal article
EID:

2-s2.0-84892760291

Part of ISBN:

11791918 11732563

Contributors: Spallone, G.; Botti, E.; Pinetti, V.; Bavetta, M.; Pavlidis, A.; Chimenti, S.; Costanzo, A.
Source: Self-asserted source
Mauro Bavetta via Scopus - Elsevier

Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab

British Journal of Dermatology
2013 | Journal article
EID:

2-s2.0-84881598576

Part of ISBN:

00070963 13652133

Contributors: Talamonti, M.; Botti, E.; Galluzzo, M.; Teoli, M.; Spallone, G.; Bavetta, M.; Chimenti, S.; Costanzo, A.
Source: Self-asserted source
Mauro Bavetta via Scopus - Elsevier

Adalimumab in the treatment of plaque-type psoriasis and psoriatic arthritis.

Expert opinion on biological therapy
2013-09-01 | Journal article
Source: Self-asserted source
Mauro Bavetta
grade
Preferred source (of 2)‎

Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: A retrospective study

Clinical and Developmental Immunology
2012 | Journal article
EID:

2-s2.0-84862297721

Part of ISBN:

17402522 17402530

Contributors: Teoli, M.; Zangrilli, A.; Chimenti, M.S.; Talamonti, M.; Bavetta, M.; Graceffa, D.; Perricone, R.; Chimenti, S.
Source: Self-asserted source
Mauro Bavetta via Scopus - Elsevier

Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.

Dermatology (Basel, Switzerland)
2012-12-28 | Journal article
Source: Self-asserted source
Mauro Bavetta
grade
Preferred source (of 2)‎

Ustekinumab for treatment of plaque psoriasis in a patient with Down syndrome.

Journal of drugs in dermatology : JDD
2012-08-01 | Journal article
Source: Self-asserted source
Mauro Bavetta